JMP Securities Reiterates Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
JMP Securities reaffirmed their market outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $114.00 price objective on the biotechnology company’s stock. Several other equities research analysts have also commented on the stock. Citigroup lifted their price target on […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.04) by $0.22, Briefing.com reports. Blueprint Medicines had a negative return on equity of 163.89% and a negative net margin of 203.30%. The firm […]
Mraz Amerine & Associates Inc. lessened its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 4.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,311 shares of the biotechnology company’s stock after selling 260 shares during the period. Mraz […]
Blueprint Medicines (NASDAQ:BPMC) Reaches New 52-Week High on Strong Earnings theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.